ArticleInfluenza and other respiratory viruses2014
Respiratory syncytial virus- and human metapneumovirus-associated emergency department and hospital burden in adults.
Article in Influenza and other respiratory viruses, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06286007 (Prevalence and Impact of Pertussis and RSV on Asthma Severity and Control), which is not on this map. Cited by 80 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Prevalence and Impact of Pertussis and RSV on Asthma Severity and Control
Who cites it
80 citing papers in PubMed, 5 syntheses or guidelines pooled it, 139 citations in OpenAlex.
- Pooled it
- Nucleic Acid-based Testing for Noninfluenza Viral Pathogens in Adults with Suspected Community-acquired Pneumonia. An Official American Thoracic Society Clinical Practice Guideline.American journal of respiratory and critical care medicine · 2021Guideline
- The burden of respiratory syncytial virus in adults: a systematic review and meta-analysis.Epidemiology and infection · 2020Pooled it
- Respiratory syncytial virus in the Western Pacific Region: a systematic review and meta-analysis.Journal of global health · 2019Pooled it
- The epidemiology of medically attended respiratory syncytial virus in older adults in the United States: A systematic review.PloS one · 2017Pooled it
- Bivalent RSVpreF Vaccine in Adults 18 to <60 Years Old With High-Risk Conditions.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025Trial
- Immunogenicity and Safety Following 1 Dose of AS01E-Adjuvanted Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults: A Phase 3 Trial.The Journal of infectious diseases · 2024Trial
- Twenty-five years of human metapneumovirus research.Clinical microbiology reviews · 2026Review
- Simultaneous Diffuse Alveolar Hemorrhage and Acute Myocarditis in an Immunocompetent Adult with a Human Metapneumovirus Infection.Internal medicine (Tokyo, Japan) · 2026Article
- Country-Level RSV-Related Hospitalisation Rates Among Adults in High-Income Countries From an Ensemble Model Based on Direct Viral Testing Incidence Data.Influenza and other respiratory viruses · 2026Article
- Comparison of Human Metapneumovirus- and Respiratory Syncytial Virus-Associated Health Burden in Adults With Chronic Underlying Health Conditions: A Global Systematic Review and Meta-analysis.Open forum infectious diseases · 2026Article
- Hospitalization Burden Estimates of Respiratory Syncytial Virus With Adjustment for Case Underascertainment in Adults Aged 18 to 65 Years in High-Income Countries: A Systematic Review, Meta-Analysis, and Modeling Study.Open forum infectious diseases · 2026Article
- Article
- Respiratory viral infections in hospitalized adults: a comparative clinico-laboratory study of RSV, HMPV, and influenza.Virology journal · 2025Article
- The Burden of Human Metapneumovirus (hMPV) Disease in Older and High-Risk Adults in Developed Countries: A Systematic Literature Review.Infectious diseases and therapy · 2025Article
- Respiratory Syncytial Virus and Human Metapneumovirus Respiratory Hospitalizations and Outcomes in Colorado Adults ≥50 Years of Age: 2016-2023.The Journal of infectious diseases · 2025Article
- The Burden of HMPV- and Influenza-Associated Hospitalizations in Adults in New Zealand Before and After the COVID-19 Pandemic, 2012-2023.The Journal of infectious diseases · 2025Article
- Seasonal Incidence of Human Metapneumovirus in High-Risk Adults With Medically Attended Acute Respiratory Illness in a Rural US Community.Influenza and other respiratory viruses · 2025Article
- Human Metapneumovirus: A Comprehensive Epidemiological Analysis of a Global Respiratory Threat.Infection & chemotherapy · 2025Review
- Epidemiology and genetic diversity of respiratory syncytial virus in adults 50 years and older with acute respiratory infections in Accra, Ghana.BMC infectious diseases · 2025Article
20 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
objectiveDetermine the burden of illness associated with respiratory syncytial virus (RSV) and human metapneumovirus (HMPV) in adults, especially young adults.
designProspective surveillance study using RT-PCR for the diagnosis of RSV and HMPV.
settingOne academic Emergency Department (ED), one academic hospital and three middle Tennessee community hospitals. SAMPLE: We prospectively enrolled Middle Tennessee residents ≥18 years old evaluated in the emergency department (ED) or hospitalized for respiratory symptoms May 2009 through April 2010. We collected nose/throat specimens for RSV and HMPV reverse-transcriptase polymerase chain reaction (RT-PCR) testing and obtained demographic and clinical data.
main outcome measuresRates of ED visits and hospitalizations were calculated using the proportion of enrolled patients positive for each virus multiplied by the number of Middle Tennessee residents evaluated in EDs and/or hospitalized in Tennessee for acute respiratory illness during the study period.
resultsThree thousand two hundred and fifty six patients were eligible; 1477 (45·4%) were enrolled; 1248 (84·5%) of these consented to additional testing and had adequate samples. RT-PCR identified 32 (2·6%) patients with RSV and 33 (2·6%) with HMPV. The median duration of symptoms before ED presentation was 3·3 days with RSV and 2·8 days with HMPV, and before hospital admission was 4·5 days with RSV and 3·5 days with HMPV. The annual hospitalization and ED visit rates were similar for RSV and HMPV. The hospitalization rate associated with each virus was about 10 per 10 000 persons aged ≥50 years; ED rates were approximately 2 times higher. Hospitalization rates were about 2 per 10 000 persons aged 18-49 years, with ED rates 5-6 times higher.
conclusionRSV and MPV are associated with substantial disease in adults, with hospitalization and ED visits rates increasing with age.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.